Journal Article

Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study

Chen, Shumin, He, Jianfeng, Huang, Peichu, Cai, Dongchun, Lai, Yuzheng, Zhou, Liang, Sun, Hao, Wu, Qing

2022

Overview

Medical treatment for stroke prevention in cryptogenic stroke (CS) patients with patent foramen ovale (PFO) remains inconclusive. We compared the efficacy and safety of dabigatran with aspirin on stroke prevention for patients with recent CS and PFO. In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group. Patients were followed for 2 years and the primary efficacy outcome was the recurrence of stroke or systemic embolism. The primary safety outcome was occurrence of bleeding complications. A total of 375 patients were enrolled in the study, 188 assigned to the dabigatran group and 187 to the aspirin group. During the 2-year follow-up, the primary efficacy outcomes occurred in 4 patients in the dabigatran group (annualized rate, 2.0%) and 11 patients in the aspirin group (annualized rate, 5.1%) (hazard ratio, 0.74; 95% confidence interval, 0.51–0.98; P = 0.049). TIA/acute ischemic stroke occurred in 3 patients in the dabigatran group and 8 patients in the aspirin group (hazard ratio, 0.72; 95% confidence interval, 0.52–0.95; P = 0.039). Bleeding complications occurred in 8 patients in the dabigatran group (annualized rate, 3.9%) and in 7 patients in the aspirin group (annualized rate, 3.5%) (hazard ratio, 1.24; 95% confidence interval, 1.01–1.52; P = 0.886). For cryptogenic stroke with PFO, dabigatran was superior to aspirin for stroke prevention. There is no increased risk of bleeding complication with dabigatran. •Dabigatran better lowered the reoccurrence of TIA/stroke and systemic embolism for patients with cryptogenic stroke and patent foramen ovale.•There no differences on the cardiovascular events between dabigatran group and aspirin group.•As compared to aspirin, dabigatran did not increase the risk of bleeding complications in the population.

• Publisher: Elsevier B.V,Elsevier Limited
• Subject: Anticoagulants / Aspirin / Aspirin - adverse effects / Asymptomatic / Atherosclerosis / Bleeding / Cardiac arrhythmia / Confidence intervals / Cryptogenic stroke / Dabigatran / Dabigatran - adverse effects / Diabetes / Embolism / Embolisms / Foramen Ovale, Patent - complications / Foramen Ovale, Patent - drug therapy / Heart attacks / Hemorrhage / Humans / Hypertension / Ischemia / Ischemic Stroke / Magnetic resonance imaging / Medical imaging / Medical treatment / Mortality / Neurology / Neurosurgery / Patent foramen ovale / Patients / Prospective Studies / Recurrence / Risk Factors / Secondary Prevention / Statistical analysis / Stroke / Stroke - epidemiology / Stroke - etiology / Stroke - prevention & control / Transient ischemic attack / Veins & arteries